Medical Marijuana Benefits and the United States Government Patent — From HHS Paper To The Open DEA Hearing Transcript

The federal government has spent decades telling Americans that cannabis has “no currently accepted medical use.” It has also spent decades owning a patent that says the opposite.

U.S. Patent 6,630,507, titled “Cannabinoids as antioxidants and neuroprotectants,” was issued on October 7, 2003, and assigned to the Department of Health and Human Services. The inventors — Aidan Hampson, Julius Axelrod, and Maurizio Grimaldi, working out of the National Institute of Mental Health — described cannabinoids as useful against oxidative damage in the brain, including in Alzheimer’s disease, Parkinson’s disease, and stroke. You can still pull the grant from the USPTO record. The National Cancer Institute’s PDQ on cannabis and cannabinoids has, for years, catalogued the same medical literature the patent was built on.

That is not a loophole. That is the state talking out of both sides of its mouth: Schedule I in the criminal code, neuroprotectant in the patent office.

Mexico’s courts treated adult-use cannabis as a human-rights question. Canada legalized nationwide in 2018. The United States kept the plant next to heroin on the federal schedule while states built medical and adult-use markets around the prohibition. The death counts never matched the classification. Alcohol, prescription opioids, and over-the-counter drugs fill the overdose tables. Cannabis does not. A substitution survey that reformers have cited for years found patients dropping prescriptions, alcohol, and illicit drugs once they had legal cannabis — which is precisely the market threat that made Schedule I so useful to anyone selling a pill with a patent of their own.

From A Patent To A Hearing Room In Arlington

The schedule finally moved, and then it stalled in the way Washington stalls things it does not want to finish.

President Biden ordered a scientific review in 2022. HHS recommended Schedule III in 2023. DEA published a proposed rule in 2024. On December 18, 2025, President Trump signed an executive order on increasing medical marijuana and cannabidiol research. On April 23, 2026, Acting Attorney General Todd Blanche issued an order immediately placing FDA-approved marijuana products and state-licensed medical marijuana products in Schedule III, and DEA set an expedited hearing on whether marijuana as a whole — not just those two buckets — should move with them.

That hearing ran from June 29 to July 15, 2026, at the DEA facility in Arlington, Virginia, before Chief Administrative Law Judge Derek Julius. The agency came in as the proponent of Schedule III. The seven “interested persons” it seated as parties all opposed the move. NORML and other reform groups were told they had not shown they were “adversely affected.” NORML’s answer was the obvious one: it wants the plant off Schedule I entirely and regulated under a cannabis-specific statute, so a half-measure to Schedule III does in fact aggrieve its members. Julius declined to reopen the participant list.

Inside the room, government attorneys argued that cannabis has currently accepted medical use for pain, nausea, and anorexia, that millions of patients already use it under state programs, and that its risks line up with substances already sitting in less restrictive schedules. One government attorney, James Schwartz, said the quiet part: cannabis can no longer remain in Schedule I. Opponents leaned on impaired driving, youth access, and the claim that a Schedule III tag would be read as a federal blessing.

Post-hearing briefs were due August 17, 2026. On August 21, Julius ordered 294 mostly technical corrections to a 2,533-page transcript and said the cleaned record would be posted to DEA.gov. MJBizDaily confirmed on August 26, 2026 that the cleaned 2,533-page record is live on DEA.gov. Cannabis Business Times later reported that DEA spent the hearing trying to discredit nearly every opposing witness, and that the recommendation may turn less on whether opponents proved a Schedule I listing than on whether they disproved the government’s Schedule III evidence.

The DEA itself asked Julius to “expeditiously recommend” that marijuana move from Schedule I to Schedule III. Closing the hearing, Julius promised counsel and the public that he would “thoroughly consider and evaluate all the evidence.” As of the first of September 2026, the judge is still writing that recommendation to the DEA Administrator. Anti-rescheduling groups have already asked courts to stay the April 23 order. Schedule III is not descheduling. It would ease research and tax treatment under 280E. It would not, by itself, make a state dispensary a federally legal storefront, and it would not erase the people still being prosecuted for the same plant HHS patented in 2003.

The patent was always the tell. A government that files 6,630,507 and then raids patients is not confused about the chemistry. It is protecting a classification. Whether Schedule III is a genuine turning point or a stall dressed up as science is the question the Arlington record now has to answer — and the judge has not answered it yet.

The same plant’s industrial cousin — fuel, hempcrete, feed, fabric — is covered in our report on nine uses for hemp the mainstream press still undersells. The opioid-craving research sits in the CBD trial that tested cannabis against addiction. For how Washington shields other monopolies, see the senators who voted against auditing the Federal Reserve. More of this beat is in Health News from The AEGIS Alliance.